Circulating tumour-derived predictive biomarkers in oncology.
Molecular characterization of tumour material will become increasingly important in selecting patients for clinical trials and offering appropriate treatment for patients in clinical practice. Recent advances in the field have indicated that the molecular characteristics of a tumour can be determined from circulating tumour cells and circulating tumour DNA; thus, a simple blood sample could provide these data in a simple, convenient and efficient manner. This article discusses progress towards guiding treatment decisions through measuring tumour-derived factors in the circulation.
Hodgson
Darren R
DR
Oncology Therapy Area, AstraZeneca, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK. darren.hodgson@astrazeneca.com
Wellings
Robert
R
Orr
Maria C M
MC
McCormack
Rose
R
Malone
Michael
M
Board
Ruth E
RE
Cantarini
Mireille V
MV
D014408:Biomarkers, Tumor / Q000097:blood*; D015179:Colorectal Neoplasms / Q000097:blood / Q000235:genetics; D004273:DNA, Neoplasm / Q000097:blood*; D006801:Humans; D008175:Lung Neoplasms / Q000097:blood / Q000235:genetics; D009369:Neoplasms / Q000097:blood* / Q000188:drug therapy* / Q000235:genetics; D009360:Neoplastic Cells, Circulating; D018579:Patient Selection
D014408:Biomarkers, Tumor; D004273:DNA, Neoplasm